Article
Palbociclib interferes with replication origin firing in a pRb independent manner
2022-09-22
Abstract excerpt
Over the last decade, CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have emerged as promising anticancer drugs. Numerous studies have demonstrated that CDK4/6 inhibitors efficiently block the pRb-E2F pathway and induce cell cycle arrest in pRb-proficient cells. Based on these studies, the inhibitors have been approved by the FDA for treatment of advanced hormonal receptor (HR) positive breast cancers...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cdf7e974-8e71-5531-9ff4-dcfcd297cac9
- DOI
- 10.1101/2022.09.21.508850
